CTI-1601 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 11, 2019 → Oct 31, 2020
NCT ID
NCT04176991About CTI-1601 + Placebo
CTI-1601 + Placebo is a phase 1 stage product being developed by Larimar Therapeutics for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT04176991. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04519567 | Phase 1 | Completed |
| NCT04176991 | Phase 1 | Completed |
Competing Products
20 competing products in Friedreich Ataxia